Third generation synthetic progestogen which is structurally related to progesterone.It has been used as a part of only-one-component contraceptives which have one year lasting effect for subdermal implants. Also orally used alone or associated to estrogen (see info on Estradiol + Nomegestrol). In a study comparing effects on breastfeeding women (120 with a Nomegestrol implant and 120 with an intrauterine device (IUD), there were no significant differences on duration of breastfeeding nor somatic follow-up criteria nor health issues in infants (Abdel -Aleem 1996). There is controversy about whether an early implant in the first few days after delivery affects milk production. Some authors consider it safer to wait for 4 to 6 weeks (ABM 2015). Because there is less published experience than with other drugs in the same group, alternatives known as safer and of shorter half life may be preferable. Progestogens in general are considered the contraceptive of choice during breastfeeding since they neither affect excretion and composition of the milk nor cause side effects nor affect the growth of the infants and the duration of lactation.Progestogen implants are considered a good choice in women who are breastfeeding (Meckstroth 2001). During lactation, progestogen-only contraceptives are preferred over those combined with estrogen. Otherwise, those with lower doses of estrogen should be used.Within the first 6 weeks postpartum, non-hormonal contraceptive methods should be the first option. There is a controversy on whether milk production is decreased when progestogens are used prior breastfeeding is well established. See below the information of these related products: